BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38268521)

  • 1. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis.
    Okubo N; Sugawara S; Fujiwara T; Sakatsume K; Doman T; Yamashita M; Goto K; Tateishi M; Suzuki M; Shirakawa R; Eura Y; Kokame K; Hayakawa M; Matsumoto M; Kawate Y; Miura M; Takiguchi H; Soga Y; Shirai S; Ando K; Arai Y; Nakayoshi T; Fukumoto Y; Takahama H; Yasuda S; Tamura T; Watanabe S; Kimura T; Yaoita N; Shimokawa H; Saiki Y; Kaikita K; Tsujita K; Yoshii S; Nakase H; Fujimaki SI; Horiuchi H
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102284. PubMed ID: 38268521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.
    Tauber H; Ott H; Streif W; Weigel G; Loacker L; Fritz J; Heinz A; Velik-Salchner C
    Anesth Analg; 2015 Apr; 120(4):730-6. PubMed ID: 25565317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of extracorporeal membrane oxygenation treatments on acquired von Willebrand syndrome in patients with out-of-hospital cardiac arrest: a retrospective observational study.
    Chiba Y; Goto K; Suzuki M; Horiuchi H; Hayakawa M
    Thromb J; 2024 May; 22(1):46. PubMed ID: 38822325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Aortic Valve Stenosis.
    Frank RD; Lanzmich R; Haager PK; Budde U
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):229-234. PubMed ID: 27481874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
    J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.
    Deconinck S; Tersteeg C; Bailleul E; Delrue L; Vandeputte N; Pareyn I; Itzhar-Baikian N; Deckmyn H; De Meyer SF; Vanderheyden M; Vanhoorelbeke K
    Res Pract Thromb Haemost; 2018 Oct; 2(4):762-766. PubMed ID: 30397685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies.
    Favaloro EJ; Oliver S; Mohammed S; Vong R
    Haemophilia; 2020 May; 26(3):503-512. PubMed ID: 32159272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
    Tiede A; Priesack J; Werwitzke S; Bohlmann K; Oortwijn B; Lenting P; Eisert R; Ganser A; Budde U
    J Thromb Haemost; 2008 Apr; 6(4):569-76. PubMed ID: 18208537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
    Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpectedly High Prevalence of Acquired von Willebrand Syndrome in Patients with Severe Aortic Stenosis as Evaluated with a Novel Large Multimer Index.
    Tamura T; Horiuchi H; Imai M; Tada T; Shiomi H; Kuroda M; Nishimura S; Takahashi Y; Yoshikawa Y; Tsujimura A; Amano M; Hayama Y; Imamura S; Onishi N; Tamaki Y; Enomoto S; Miyake M; Kondo H; Kaitani K; Izumi C; Kimura T; Nakagawa Y
    J Atheroscler Thromb; 2015; 22(11):1115-23. PubMed ID: 26269004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
    Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
    Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
    Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
    Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
    J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay.
    Chen D; Tange JI; Meyers BJ; Pruthi RK; Nichols WL; Heit JA
    J Thromb Haemost; 2011 Oct; 9(10):1993-2002. PubMed ID: 21824283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in von Willebrand Factor Multimers, Concentration, and Function During Pediatric Extracorporeal Membrane Oxygenation.
    Van Den Helm S; Letunica N; Barton R; Weaver A; Yaw HP; Karlaftis V; McCafferty C; Cai T; Newall F; Horton SB; Chiletti R; Johansen A; Best D; McKittrick J; Butt W; d'Udekem Y; MacLaren G; Linden MD; Ignjatovic V; Monagle P
    Pediatr Crit Care Med; 2023 Apr; 24(4):268-276. PubMed ID: 36602314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.